Immunoglobulin G Fc region binding polypeptide
US-9175067-B2 · Nov 3, 2015 · US
HER2 binders
US10159760B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10159760-B2 |
| Application number | US-201615083424-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 29, 2016 |
| Priority date | Dec 22, 2010 |
| Publication date | Dec 25, 2018 |
| Grant date | Dec 25, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of imaging at least a portion of a subject comprising: administering a composition to the subject, wherein the composition comprises an isolated polypeptide comprising SEQ. ID No. 2 conjugated with a 99m Tc via a diaminedioxime chelator, and wherein the isolated polypeptide binds specifically to HER2; and imaging the subject with a SPECT device. 2. The method of claim 1 , further comprising the step of: diagnosing the subject with a HER2 expressing cancer. 3. The method of claim 2 , wherein the HER2 expressing cancer is breast cancer. 4. The method of claim 1 , wherein the diaminedioxime chelator is cPn216. 5. The method of claim 1 , wherein the 99m Tc is conjugated to the isolated polypeptide via the cPn216 chelator at the N-terminus of the isolated polypeptide. 6. The method of claim 1 , further comprising the step of: monitoring delivery of the composition to the subject.
Assignees
Inventors
Classifications
for growth factors; for growth regulators · CPC title
- A61K51/088Primary
conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10159760B2 cover?
- Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.
- Who is the assignee on this patent?
- Gen Electric, Affibody Ab
- What technology area does this patent fall under?
- Primary CPC classification A61K51/088. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 25 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).